tbuckley/cabot-search huggingface dataset:
Screening for Depression: Recommendations from the U.S. Preventive Services Task Force
Journal: Annals of Internal Medicine (2002)

Summaries for Patients21 May 2002Screening for Depression: Recommendations from the U.S. Preventive Services Task ForceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-10-200205210-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the U.S. Preventive Services Task Force?The U.S. Preventive Services Task Force (USPSTF) is a group of health experts that reviews published research and makes recommendations about preventive health care.What is the problem and what is known about it so far?Depression causes sadness that interferes with daily life. Depression is a medical condition, not a normal reaction to a life situation such as the death of a loved one or the loss of a job. About 1 out of every 5 people suffers depression at some time in his or her life, and depression is common ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full reports titled “Screening for Depression: Recommendations and Rationale” and “Screening for Depression in Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force.” They are in the 21 May 2002 issue of Annals of Internal Medicine (volume 136, pages 760-764 and pages 765-776). The first report was written by the U.S. Preventive Services Task Force; the second report was written by MP Pignone, BN Gaynes, JL Rushton, CM Burchell, CT Orleans, CD Mulrow, and KN Lohr.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians–American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoScreening for Depression: Recommendations and RationaleScreening for Depression in Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force Michael P. Pignone , Bradley N. Gaynes , Jerry L. Rushton , Catherine Mills Burchell , C. Tracy Orleans , Cynthia D. Mulrow , and Kathleen N. Lohr Metrics 21 May 2002Volume 136, Issue 10Page: I-56KeywordsAdolescentsChildrenComputed axial tomographyDepressionEmotionsHealth careHealth care providersMedical conditionsPreventive medicine ePublished: 21 May 2002 Issue Published: 21 May 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The diagnostic utility of the febrile agglutinin tests
Authors: T. J. Zuerlein
Journal: JAMA (1985)

The purpose of our study was to analyze the use of febrile agglutinin (FA) serologic tests in the diagnosis of<i>Salmonella (typhi and paratyphi), Rickettsia, Brucella, and Francisella</i>infections. Data were collected in a retrospective chart study of 202 titer requests covering a 42-month period at our teaching hospital. We found that no diagnoses were made by utilizing complete six-antigen FA panels. Three cases of infection were diagnosed serologically, all three with more discriminately selected single-antigen titers. These three cases each had a positive epidemiological history suggestive of disease prior to ordering FA tests. Our data suggest that the FA tests (especially the<i>Salmonella</i>group antigen) are an overutilized set of laboratory tests and are often difficult to interpret. It is much more important to make a diagnosis based on clinical findings and epidemiological criteria. (<i>JAMA</i>1985;254:1211-1214)
&lt;title&gt;State Medical Associations and Examinations and Licensure&lt;/title&gt;I. State Boards of Medical Examiners&lt;BREAK /&gt;II. Medical Specialty Boards
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caring for all of those who fall in combat
Authors: M. F. Goldsmith
Journal: JAMA (1992)

THE NEED for a safe, effective means of anesthesia delivery to support US combat troops has been recognized ever since the Civil War, according to Brian F. Condon, MD, chief of anesthesia at Walter Reed Army Medical Center, Washington, DC. Although much research has gone into providing this support, he says, oddly enough the compact piece of equipment that has received much attention lately is basically similar to what might have been used on a soldier hit by a minié ball in the Civil War—even if it is small enough to be delivered by a parachute from aircraft today. <h3>Just Essentials</h3> Known as the Ohmeda PAC (Portable Anesthesia Complete), this is simply a draw-over vaporizer, a device that allows the patient to breathe in anesthesia without the need for oxygen. Condon, who is a colonel in the US Army Medical Corps and consultant for anesthesia to the Surgeon General of
Diet in Health and Disease.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Applied Physiology
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiogenic Shock
Authors: Steven M. Hollenberg, Clifford J. Kavinsky, Joseph E. Parrillo
Journal: Annals of Internal Medicine (1999)

To review the cause, epidemiology, pathophysiology, and treatment of cardiogenic shock.A MEDLINE search of the English-language reports published between 1976 and 1998 and a manual search of bibliographies of relevant papers.Experimental, clinical, and basic research studies related to cardiogenic shock.Data in selected articles were reviewed, and relevant clinical information was extracted.Cardiogenic shock is a state of inadequate tissue perfusion due to cardiac dysfunction, most commonly caused by acute myocardial infarction. Mortality rates for patients with cardiogenic shock remain frustratingly high, ranging from 50% to 80%. The pathophysiology of cardiogenic shock involves a downward spiral: Ischemia causes myocardial dysfunction, which, in turn, worsens ischemia. Areas of nonfunctional but viable (stunned or hibernating) myocardium can also contribute to the development of cardiogenic shock. The key to achieving a good outcome is an organized approach that includes rapid diagnosis and prompt initiation of therapy to maintain blood pressure and cardiac output. Expeditious coronary revascularization is crucial. When available, emergency cardiac catheterization and angioplasty seem to improve survival. More recent developments, such as placement of coronary stents and use of glycoprotein IIb/IIIa antagonists, are promising but have not yet been well studied in patients with cardiogenic shock. In hospitals without direct angioplasty capability, stabilization with intra-aortic balloon counterpulsation and thrombolysis followed by transfer to a tertiary care facility may be the best option.Improved understanding of the pathophysiology of shock and myocardial infarction has led to improved treatment. If cardiogenic shock is managed with rapid evaluation and prompt initiation of supportive measures and definitive therapy, outcomes can be improved.
P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status
Authors: P Y Wen, J de Groot, J D Battiste, S A Goldlust, J Garner, J Simpson, A Olivero, T Cloughesy
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR). The PI3K pathway is activated in ≥ 70% of tumors, making it a compelling target for the treatment of GBM. GDC-0084 crosses the blood-brain barrier and achieves a brain / plasma ratio of approximately 1.0. GDC-0084 was given as once daily oral dosing in a phase 1 study (Wen et al, J Clin Oncol 34, 2016(15) suppl.2012) in 47 patients with recurrent high-grade gliomas. The adverse events were generally consistent with the established PI3K/mTOR inhibitor class-effects. The MTD identified was 45 mg once daily. MATERIAL AND METHODS This study has a 2-part design consisting of an open-label, multicenter dose-escalation study with expansion to assess the safety, tolerability, RP2D, PK, and clinical activity of GDC-0084 at QD dosing in patients with newly-diagnosed GBM with unmethylated MGMT promotor status. In the escalation phase the first cohort is completed without DLT. At the identified MTD, 20 subjects will be recruited in an expansion cohort and patients will be randomized to take GDC-0084 in fed and fasted states. Subjects in the expansion cohort will also have serial fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging.
Blood Diseases
Authors: William R. Best
Journal: JAMA (1964)

I am ambivalent about this volume. As an addition to my hematological references it will be consulted from time to time, especially for the tabulations of manifestations according to key publications on a disease. These are the strength of the book and form the nucleus around which it is built. Diverse reports on rare conditions are made particularly digestible in this fashion. Such juxtaposition also makes apparent the weaknesses of many published reports. Does a blank in a table mean that a given manifestation was not present, that it was not looked for, or that data were not included in a publication? For example, of eight tabulated studies on pernicious anemia only one mentions weight loss, reporting its presence in 93% of patients (42 of 44 patients with adequate information, but 25 patients from this study did not have adequate information). If weight loss was so prominent, why did the
Abstract 2409: Predictive accuracy of Cox proportional hazards cure models with application in cancer studies
Authors: Xiaoxia Han, Yilong Zhang, Yongzhao Shao
Journal: Cancer Research (2019)

Abstract With recent development in cancer screening, diagnosis and treatment, many early-stage cancer patients will never experience recurrence, metastasis or death due to their primary cancer, whom can be considered as clinically cured. In the era of precision medicine, it is of interest to develop predictive models for cure status as well as for survival among uncured patients. The area under the ROC curve (AUC) is commonly used for assessing discriminative accuracy for dichotomous outcome (cured/uncured). Yet the conventional AUC cannot be directly used here due to unobserved cured status. In this study, we extend the conventional AUC to Cox proportional hazards (PH) cure models for evaluating prognostic utility in the presence of latent cured patients. We develop consistent and asymptotically normal estimates with explicit formulas for sensitivity, specificity and AUC. Furthermore, we reviewed the prognostic accuracy estimators for survival time among uncured patients for Cox PH cure models. Numerical studies show that our proposed estimators perform well for finite sample size. A melanoma data is used to illustrate the utility of our proposed prognostic metrics. We also have developed an R package called evacure to efficiently compute these estimates and their confidence intervals. Citation Format: Xiaoxia Han, Yilong Zhang, Yongzhao Shao. Predictive accuracy of Cox proportional hazards cure models with application in cancer studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2409.
Canadian Psychiat Assoc Journal, Ottawa
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).
Authors: Yun Chen, Kuaile Zhao, Jingjun Ye, Zhengfei Zhu, Weixin Zhao, Ling Li, Jialiang Zhou, Chaoyang Wu, Huarong Tang, Gang Xu, Qin Lin, Jiancheng Li, Yi Xia, Yunhai Li, Zhen Zhang
Journal: Journal of Clinical Oncology (2017)

4066 Background: Concurrent chemoradiotherapy (CCR) with cisplatin plus 5-Fu (PF) regimen is the standard modality for inoperable locally advanced esophageal squamous cell carcinoma (ESCC) patients. In this phase 3 trial, we aimed to assess the efficacy and safety of the paclitaxel plus 5-Fu (TF) regimen versus PF regimen in CCR for ESCC patients. Methods: ESCC patients presented with stage IIa to IVa were enrolled in a prospective multicenter phase 3 study. Patients were randomized to either PF group or TF group. Patients in PF group were treated with 2 cycles of CCR followed by 2 cycles of consolidation chemotherapy with PF (cisplatin 25 mg/m 2 /d, d1-3, plus 5-Fu 1800 mg/m 2 , civ 72h, q28d). Patients in TF group were treated with 5 cycles of weekly TF (5-Fu 300 mg/m 2 , civ 96h plus paclitaxel 50 mg/m 2 , d1) in CCR followed by 2 cycles of monthly TF (5-FU 1800 mg/m 2 , civ 72h, plus paclitaxel 175 mg/m 2 d1) in consolidation chemotherapy. The radiotherapy dose in both groups was 61.2 Gy delivered in 34 fractions. Adverse events (AE) defined according to CTCAE 4.0. The primary end-point was 3-yr OS. The number and grade of participants with AE was analyzed by intention to treat. Results: Between April 2012 and July 2015, 436 ESCC patients in 7 centers were enrolled. TF group had a significant higher incidence of acute Grade 3/4 leukopenia (31.3% vs. 18.9%), hiccup (0.9% vs. 0.0%), dermatitis (17.5% vs. 7.5%), pneumonitis (9.8% vs. 2.3%), and esophagitis (6.0% vs. 3.2%), and lower incidence of anemia (0.5% vs. 1.9%), thrombocytopenia (0.5% vs. 13.8%), fatigue (5.6% vs. 17.3%), anorexia (0.5% vs. 14.1%), nausea (0.5% vs. 14.1%), and vomiting (0.9% vs. 17.7%) than PF group (P &lt; 0.05). There were 3(1.4%) patients in TF group died of acute pneumonitis. For long-term AE, 1(0.5%) patient in each group died of pneumonitis. There was no significant difference in total numbers of incidence of ≥ Grade 3 AE between two groups. Until Jan 2017, the median survival has not reached. Conclusions: The safety results of this trial were acceptable. TF regimen showed a different AE profile compared with PF regimen used in CCR in ESCC patients. Clinical trial information: NCT01591135.
Book Review Preventing Medication Errors (Quality Chasm Series.) By the Committee on Identifying and Preventing Medication Errors and the Board on Health Care Services. Edited by Philip Aspden, Julie A. Wolcott, J. Lyle Bootman, and Linda R. Cronenwett. 463 pp. Washington, DC, National Academies Press, 2007. $54.95. 978-0-309-10147-9 Medication Errors Second edition. Edited by Michael R. Cohen. 680 pp., illustrated. Washington, DC, American Pharmacists Association, 2007. $89.95. 978-1-58212-092…
Authors: John P. Burke
Journal: New England Journal of Medicine (2007)
Acute Leukemia in the Adult Male: II. Natural History
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
My Friend
Authors: Thomas J. Poulton
Journal: JAMA (1987)

Brett is intensely curious about the rapidly enlarging world about him. His probing curiosity about life stimulates the adults around him to inquire more actively about their own lives. He is like most other 3-year-olds, I think: full of delightful mischief, granting smiles without hesitation and rapidly retreating to tears at those times when life is just too much bigger than he is. And, like many children, he cannot conceal a certain charming, if smug, satisfaction as he masters each new developmental task. Those tasks often come hard for Brett. Brett has many other friends. Some, such as I, are new friends. Others, such as Grandma, Grandpa, and Daddy, go way back to before the accident that he now pretends not to remember. The accident? Brett's mother and baby brother, Matthew, were killed by a drunk driver in a violent accident on a softly beautiful starlit evening last summer. I
SOME OF THE BLOOD-CHANGES ATTENDING TYPHOID FEVER.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal